ACADIA Pharmaceuticals Inc (MEX:ACAD)
MXN 362 (0%) Market Cap: 75.95 Bil Enterprise Value: 61.93 Bil PE Ratio: 11.51 PB Ratio: 3.47 GF Score: 73/100

ACADIA Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript

Dec 03, 2024 / 03:15PM GMT
Release Date Price: MXN509
Yigal Nochomovitz
Citigroup Global Markets Inc. - Analyst

Okay. Great. All right. Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts here at Citigroup. Welcome to Miami, our first iteration of the conference down here in Florida. So it's my great pleasure to have with me senior leadership of ACADIA Pharmaceuticals. We have the CEO, Catherine Owen Adams. Welcome. Head of R&D, Liz Thompson; and Mark Schneyer, the CFO.

Mark Schneyer
ACADIA Pharmaceuticals Inc - Chief Financial Officer, Executive Vice President

Hello, Yigal.

Questions & Answers

Yigal Nochomovitz;Catherine Owen Adams
Citigroup Global Markets Inc. - Analyst;ACADIA Pharmaceuticals Inc - Chief Executive Officer, Director

Great. Great. Thank you so much for being here. So maybe we can just kick it off with just a high-level overview of the company, the products that you're selling where you are in the trajectory with the two products in the market, and we'll get into the pipeline later.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot